Oncology Pharmacist Lunch & Lecture Series

**Thursday, August 6**
12:00 pm – 1:00 pm

**New Drug Updates: IV Therapies**

*Angela Duenn, PharmD, BCOP*
Regional Clinical Pharmacy Coordinator, Hematology-Oncology
St. Joseph Mercy Health System
Ypsilanti, Mich.

**CEU Info:**
Live Activity: ACPE Universal Activity #0112-9999-20-307-L01-P & #0112-9999-20-307-L01-T
Home Study Activity: ACPE Universal Activity #0112-9999-20-307-H01-P & #0112-9999-20-307-H01-T
1.0 Contact Hour; Knowledge-based Activity, Initial Release Date: 8/6/20; Expiration Date: 8/6/21

This presentation will provide pharmacists practicing in various settings an overview of the anticancer drug approvals in 2019. The presentation will also discuss relevant clinical trial findings and their utility in clinical practice.

**Pharmacist Learning Objectives**
At the end of this activity, participants should be able to:
1. Recall recently approved anticancer drugs.
2. Discuss novel mechanisms of drug action.
3. Describe relevant clinical findings and their utility in clinical practice.

**Pharmacy Technician Learning Objectives**
At the end of this activity, participants should be able to:
1. Recall recently approved anticancer drugs.
2. Discuss novel mechanisms of drug action.
3. Describe the impact of new drug approvals in cancer care.

**Thursday, August 20**
12:00 pm – 1:00 pm

**New Drug Updates: Oral Oncolytics**

*Claire Saadeh, PharmD, BCOP*
Professor, Pharmacy Practice
Ferris State University
Sparrow Health System
DeWitt, Mich.

**CEU Info:**
Live Activity: ACPE Universal Activity #0112-9999-20-308-L01-P & #0112-9999-20-308-L01-T
Home Study Activity: ACPE Universal Activity #0112-9999-20-308-H01-P & #0112-9999-20-308-H01-T
1.0 Contact Hour; Knowledge-based Activity, Initial Release Date: 8/20/20; Expiration Date: 8/20/21

Approximately 25% of the new chemotherapy drugs coming up for FDA approval are oral oncolytics. It is important to keep up with these drugs to ensure that patients are receiving the correct agent based on specific mutations within cancer cells, and the appropriate dosing is employed. These agents also require comprehensive patient education, adherence monitoring, safety monitoring, and side effect management that all pharmacists and technicians should be familiar with.

**Pharmacist and Pharmacy Technician Learning Objectives**
At the end of this activity, participants should be able to:
1. Identify the mechanism of action of novel oral oncolytic agents.
2. Discuss the most common and significant side effects associated with the newly approved oral oncolytic agents.
3. Summarize the current place in therapy for newly approved oral cancer drugs.

**Thursday, September 3**
12:00 pm – 1:00 pm

**Updates in Treatment of Pancreatic Cancer**

*Allison Schepers, PharmD, BCOP*
Clinical Pharmacist Specialist, Medical Oncology
University of Michigan College of Pharmacy
Ann Arbor, Mich.

**CEU Info:**
Live Activity: ACPE Universal Activity #0112-9999-20-309-L01-P & #0112-9999-20-309-L01-T
Home Study Activity: ACPE Universal Activity #0112-9999-20-309-H01-P & #0112-9999-20-309-H01-T
1.0 Contact Hour; Knowledge-based Activity, Initial Release Date: 9/3/20; Expiration Date: 9/3/21

This presentation will review the evidence and controversies surrounding the treatment of localized and metastatic pancreatic cancer, with a focus on pharmacologic therapy. Topics will include adjuvant chemotherapy options, role of neoadjuvant treatment, novel therapeutic modalities such as pegilodecakin and pegvorhyaluronidase alfa, and the role of targeted therapies such as PARP inhibitors. The presenter will also discuss the role of genetic testing in patients with pancreatic cancer. Audience members will be able to combine knowledge of primary literature, medication properties, and patient factors to select appropriate evidence-based therapy for patients with pancreatic cancer.

**Pharmacist and Pharmacy Technician Learning Objectives**
At the end of this activity, participants should be able to:
1. Evaluate the role of genetic testing and use of PARP inhibitors in patients with pancreatic adenocarcinoma.
2. Summarize recent practice-changing trials in the neoadjuvant and adjuvant settings.
3. Describe novel treatment strategies in the metastatic setting, including maintenance therapy and novel targeted therapies.

**Thursday, September 17**
12:00 pm – 1:00 pm

**Recent Advances in the Treatment of Breast Cancer**

*Ryan DasGupta, PharmD*
Clinical Pharmacy Specialist, Hematology/Oncology
Henry Ford Health System
Detroit, Mich.

**CEU Info:**
Live Activity: ACPE Universal Activity #0112-9999-20-310-L01-P & #0112-9999-20-310-L01-T
Home Study Activity: ACPE Universal Activity #0112-9999-20-310-H01-P & #0112-9999-20-310-H01-T
1.0 Contact Hour; Knowledge-based Activity, Initial Release Date: 9/17/20; Expiration Date: 9/17/21

Pharmacists will need to attain the knowledge about evolving breast cancer treatments (new drugs or indications, dosing, monitoring, side effects and management, costs, etc.) Pharmacy technicians will need to attain familiarity with new drugs that have been approved to improve their confidence and competence regarding selection and preparation of drugs.

**Pharmacist and Pharmacy Technician Learning Objectives**
At the end of this activity, participants should be able to:
1. Review pathophysiology of breast cancer including relevant biomarkers that influence medication selection.
2. Discuss the safety and efficacy of novel pharmacologic treatment strategies for various subtypes of breast cancer.
3. Identify supportive care strategies to manage common and rare toxicities of breast cancer treatments.
Registration and Delivery Format
This program will be delivered virtually through webinar. Registration will be accepted until the day of each webinar. Instructions to access the webinar will be emailed to registrants upon registration, as well as two additional times, including the day of the webinar. Register for each individual session online at www.msho.org/education and email kblazevski@msho.org with any questions.

Pharmacy Continuing Education Requirements
This activity is structured to meet knowledge-based educational needs. A knowledge-based activity acquires factual knowledge. Information in knowledge-based activities is based on evidence as accepted in the literature by the health care professions.

Live Activities
Pharmacy continuing education (PCE) credit will be earned based on participation in this activity. Any individual who is more than 10 minutes late to an activity or leaves an activity early will not be granted PCE credit. This procedure will be strictly enforced, so please plan accordingly. Participants must fully participate in the activity and complete an online activity evaluation and posttest questions, if received by presenters, with a passing score of 70 percent or greater, within 14 days of program date. Online evaluations and posttests will not be available for completion and requests to process credit will not be accepted after this date. Credit will not be processed until the online evaluation and posttest has officially closed for response. Please allow MPA two weeks to grade posttests and process and upload credit to CPE Monitor after the evaluation and posttest has closed.

Home Study Activities
Participants must complete an online activity evaluation and posttest questions, if received by presenters, with a passing score of 70 percent of greater, within 14 days of program access. Please allow MPA two weeks to grade posttests and process and upload credit to CPE Monitor.

Pharmacists and Home Study Activities
ACPE guidelines prohibit MPA from issuing credit more than 60 days after the activity for any reason; therefore, to avoid denial of credit, it is imperative that pharmacists and pharmacy technicians complete the online evaluation and posttest by the deadline indicated to allow sufficient time for processing. If all requirements are met, participants will receive pharmacy continuing education (PCE) credit through CPE Monitor, a national, collaborative effort by ACPE and the National Association of Boards of Pharmacy (NABP) to provide an electronic system for pharmacists and pharmacy technicians to track their completed PCE credits. MPA, as an ACPE-accredited provider, is required to report pharmacist and pharmacy technician PCE credit using this tracking system. Pharmacist and pharmacy technician participants must provide their NABP e-Profile identification number and date of birth (in MMDD format) when they complete activity evaluations. It will be the responsibility of the participant to provide the correct information. If this information is not correctly provided, NABP and ACPE prohibit MPA from issuing CPE credit. Partial credit will not be awarded. If you have yet to sign up for CPE Monitor, go to MyCPEMonitor.net.

Michigan Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.